1. Home
  2. HFBL vs VERU Comparison

HFBL vs VERU Comparison

Compare HFBL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home Federal Bancorp Inc. of Louisiana

HFBL

Home Federal Bancorp Inc. of Louisiana

HOLD

Current Price

$20.30

Market Cap

58.1M

Sector

Finance

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.95

Market Cap

48.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HFBL
VERU
Founded
1924
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
48.2M
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
HFBL
VERU
Price
$20.30
$2.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
1.3K
5.2M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
2.83%
N/A
EPS Growth
7.69
N/A
EPS
1.55
N/A
Revenue
$1,303,000.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.10
N/A
Revenue Growth
17.49
N/A
52 Week Low
$12.32
$0.36
52 Week High
$20.30
$7.33

Technical Indicators

Market Signals
Indicator
HFBL
VERU
Relative Strength Index (RSI) 61.01 53.55
Support Level $18.96 $2.15
Resistance Level N/A $3.68
Average True Range (ATR) 0.16 0.67
MACD 0.01 -0.00
Stochastic Oscillator 100.00 16.09

Price Performance

Historical Comparison
HFBL
VERU

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: